Search

There is growing evidence that bacteria encountered in prosthetic joint infections (PJIs) form surface-attached biofilms on prostheses, as well as biofilm aggregates embedded in synovial fluid and tissues. However, in vitro models allowing the investigation of these biofilms and the assessment of their antimicrobial susceptibility in physiologically relevant conditions are currently lacking. To address this, we developed a synthetic synovial fluid (SSF2) model and validated this model by investigating growth, aggregate formation, and antimicrobial susceptibility using multiple PJI isolates belonging to various microorganisms. In this study, 18 PJI isolates were included belonging to Staphylococcus aureus , coagulase-negative staphylococci, Cutibacterium acnes , Streptococcus spp., Enterococcus spp., Pseudomonas aeruginosa , Escherichia coli , and Candida spp. Growth and aggregate formation in SSF2 were evaluated using light microscopy and confocal laser scanning microscopy. The biofilm preventing concentration (BPC) and minimal biofilm inhibitory concentration (MBIC) of relevant antibiotics were determined using a resazurin-based viability staining. BPC and MBIC values were compared to conventional susceptibility parameters (minimal inhibitory concentration and minimal bactericidal concentration) determined with conventional approaches. The SSF2 medium allowed isolates to grow and form biofilm-like aggregates varying in size and shape between different species. For most isolates cultured in SSF2, a reduced susceptibility to the tested antibiotics was observed when compared to susceptibility data obtained in general media. These data indicate that the in vitro SSF2 model could be a valuable addition to evaluate the antimicrobial susceptibility of biofilm-like aggregates in the context of PJI., Importance: Infections after joint replacement are rare but can lead to severe complications as they are difficult to treat due to the ability of pathogens to form surface-attached biofilms on the prosthesis as well as biofilm aggregates in the tissue and synovial fluid. This biofilm phenotype, combined with the microenvironment at the infection site, substantially increases antimicrobial tolerance. Conventional in vitro models typically use standard growth media, which do not consider the microenvironment at the site of infection. By replacing these standard growth media with an in vivo -like medium, such as the synthetic synovial fluid medium, we hope to expand our knowledge on the aggregation of pathogens in the context of PJI. In addition, we believe that inclusion of in vivo -like media in antimicrobial susceptibility testing might be able to more accurately predict the in vivo susceptibility, which could ultimately result in a better clinical outcome after antimicrobial treatment.

Background: A key factor leading to impaired immunity in HIV infection is an alteration of the pattern of cytokine response, although its precise nature remains controversial, particularly the in vivo influence of HIV on interleukin (IL)-12 synthesis., Design: A cross-sectional study in 73 HIV-infected persons (28 of them receiving highly active antiretroviral therapy) and 18 HIV-seronegative healthy donors., Methods: The frequency of monocytes/macrophages (M/M) synthesizing IL-12, IL-10 and tumour necrosis factor alpha (TNF-alpha) was determined in peripheral blood mononuclear cells. The cells were cultured in medium or were stimulated with lipopolysaccharide; proportions of CD64 M/M producing IL-12, TNF-alpha or IL-10 was determined by cytofluorometric analysis. The influence of exogenous interferon gamma (IFN-gamma), IL-10 or IL-15 on IL-12 synthesis was tested., Results: Chronic HIV disease is associated with increased priming of M/M for IL-12 (involving both p40 and p70 molecules) and TNF-alpha synthesis; this was associated with cosynthesis of both cytokines by a fraction of M/M. Priming for IL-12 was physiologically enhanced by IFN-gamma and decreased by IL-10; IL-15 had no effect. The proportion of IL-10-producing CD64 M/M was not altered in patients compared with controls but there was an inverse correlation between IL-10-producing M/M and viral load. IL-12 production was not correlated with viral load but was increased following antiretroviral therapy. Following LPS stimulation, IL-12 and TNF-alpha responses were not altered in HIV-positive patients; however, the IL-10 response was decreased but restored by antiretroviral therapy., Conclusion: These observations argue for a preserved intrinsic CD64 M/M of IL-12 production in HIV pathogenesis.

A total of 151 previously untreated patients infected with human immunodeficiency virus type 1 (HIV-1) with CD4 cell counts >/=200/microL and plasma HIV-1 RNA levels of 10,000-100,000 copies/mL were randomly assigned to 24 weeks of open-labeled stavudine plus didanosine (group 1), zidovudine plus lamivudine (group 2), or stavudine plus didanosine followed by zidovudine plus lamivudine (group 3). The mean decrease in HIV-1 RNA level was greater in group 1 (2.26 log10 copies/mL) than in groups 2 (1.26 log10 copies/mL) or 3 (1.58 log10 copies/mL; P<.0001). The mean increase in CD4 cell counts was greater in groups 1 (124 cells/microL) and 3 (118 cells/microL) than in group 2 (62 cells/microL; P=.02). All regimens were generally well tolerated. The combination of stavudine plus didanosine reduced plasma HIV-1 RNA concentrations and increased CD4 cell counts more effectively than did the combination of zidovudine plus lamivudine or the regimen alternating both combinations.